

eMeasure Title	Pregnant women that had HBsAg testing		
eMeasure Identifier (Measure Authoring Tool)	158	eMeasure Version number	6.0.000
NQF Number	Not Applicable	GUID	3bbfc929-50c8-44b8-8d34-82be75c08a70
Measurement Period	January 1, 20XX through December 31, 20XX		
Measure Steward	Optum		
Measure Developer	Optum		
Endorsed By	None		
Description	This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy		
Copyright	This measure is copyrighted by Optum, Inc. All rights reserved.		
Disclaimer	<p>The information in this document is subject to change without notice. This documentation contains proprietary information, and is protected by U.S. and international copyright. All rights reserved. No part of this documentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, modifying, or recording, without the prior written permission of Optum, Inc. No part of this documentation may be translated to another program language without the prior written consent of Optum, Inc.</p> <p>Optum(R), Symmetry(R), EBM Connect(R), service marks and logos are registered and unregistered trademarks of Optum and its affiliates in the United States and other countries.</p> <p>CMS has contracted with Mathematica Policy Research and its subcontractor, Telligen, for the continued maintenance of this electronic measure.</p> <p>EBM Connect(R), Release 9.0, 2015.</p> <p>Due to technical limitations, registered trademarks are indicated by (R) or [R].</p>		
Measure Scoring	Proportion		
Measure Type	Process		
Stratification	None		
Risk Adjustment	None		
Rate Aggregation	None		
Rationale	The U.S. Preventive Services Task Force (USPSTF) found good evidence that universal prenatal screening for hepatitis B virus (HBV) infection using hepatitis B surface antigen (HBsAg) substantially reduces prenatal transmission of HBV and the subsequent development of chronic HBV infection (USPSTF 2009). The current practice of vaccinating all infants against HBV infection and post-exposure prophylaxis with hepatitis B immune globulin administered at birth to infants of HBV-infected mothers substantially reduces the risk for acquiring HBV infection.		
Clinical Recommendation Statement	The U.S. Preventive Services Task Force (USPSTF) strongly recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit (USPSTF 2009). This is a grade A* recommendation from the USPSTF. In addition, the American College of Obstetricians and Gynecologists (ACOG) recommend screening all pregnant women for HBV infection (ACOG 2007).		
Improvement Notation	Higher score indicates better quality		
Reference	U.S. Preventive Services Task Force. Screening for Hepatitis B Virus Infection in Pregnancy: U.S.Preventive Services Task Force Reaffirmation Recommendation Statement. Ann Int Med 2009;150:869-73.		
Reference	American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol 2007;110:941-56.[PMID: 17906043]		
Definition	None		
Guidance	None		
Transmission Format	TBD		
Initial Population	All female patients aged 12 and older who had a live birth or delivery during the measurement period		
Denominator	Equals Initial Population		
Denominator	None		

Exclusions	
Numerator	Patients who were tested for hepatitis B surface antigen (HBsAg) during pregnancy within 280 days prior to delivery
Numerator Exclusions	Not Applicable
Denominator Exceptions	Patients with a diagnosis of hepatitis B that started or ended within 365 days prior to delivery
Supplemental Data Elements	For every patient evaluated by this measure also identify payer, race, ethnicity and sex

Table of Contents

- [Population Criteria](#)
- [Data Criteria \(ODM Variables\)](#)
- [Data Criteria \(ODM Data Elements\)](#)
- [Supplemental Data Elements](#)
- [Risk Adjustment Variables](#)

Population Criteria

- Initial Population =**
 - AND: \$Delivery_Proc_Dx
 - AND: Age>= 12 year(s) at: "Measurement Period"
 - AND: "Patient Characteristic Sex: Female"
- Denominator =**
 - AND: Initial Population
- Denominator Exclusions =**
 - None
- Numerator =**
 - AND: "Laboratory Test, Performed: HBsAg" <= 280 day(s) starts before start of \$Delivery_Proc_Dx
- Numerator Exclusions =**
 - None
- Denominator Exceptions =**
 - OR: Union of:
 - "Diagnosis: Hepatitis B" <= 365 day(s) starts before start of \$Delivery_Proc_Dx
 - "Diagnosis: Hepatitis B" <= 365 day(s) ends before start of \$Delivery_Proc_Dx
- Stratification =**
 - None

Data Criteria (ODM Variables)

- \$Delivery_Proc_Dx =**
 - "Procedure, Performed: Delivery - Procedure" satisfies all:
 - Most Recent: during "Measurement Period"
 - overlaps "Diagnosis: Delivery - Diagnosis"

Data Criteria (ODM Data Elements)

- "Diagnosis: Delivery - Diagnosis" using "Delivery - Diagnosis Grouping Value Set (2.16.840.1.113883.3.67.1.101.1.278)"
- "Diagnosis: Hepatitis B" using "Hepatitis B Grouping Value Set (2.16.840.1.113883.3.67.1.101.1.269)"
- "Laboratory Test, Performed: HBsAg" using "HBsAg Grouping Value Set (2.16.840.1.113883.3.67.1.101.1.279)"
- "Patient Characteristic Sex: Female" using "Female AdministrativeGender Value Set (2.16.840.1.113883.3.560.100.2)"
- "Procedure, Performed: Delivery - Procedure" using "Delivery - Procedure Grouping Value Set (2.16.840.1.113762.1.4.1078.5)"

Supplemental Data Elements

- "Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity CDCREC Value Set (2.16.840.1.114222.4.11.837)"
- "Patient Characteristic Payer: Payer" using "Payer SOP Value Set (2.16.840.1.114222.4.11.3591)"
- "Patient Characteristic Race: Race" using "Race CDCREC Value Set (2.16.840.1.114222.4.11.836)"
- "Patient Characteristic Sex: ONC Administrative Sex" using "ONC Administrative Sex AdministrativeGender Value Set (2.16.840.1.113762.1.4.1)"

Risk Adjustment Variables

- None

Measure Set	None
-------------	------